Flash Therapeutics announces that the IRIS project, for which it is the industrial partner, has been accepted for the 4th solicitation of bids for RHU projects of the « Programme d’Investissements d’Avenir »
Flash Therapeutics, announces that the "IRIS" project has been accepted for the solicitation of bids by the « Recherche Hospitalo-Universitaire en santé » (RHU) for the Programme d'Investissement d'Avenir, supporting innovative and large-scale projects.
The IRIS project (InheRited Immune diSorders) is a gene therapy project for monogenic inherited diseases of the immune system.
To learn more, please, download the press release by clicking here .
by Yohann Moal